EXCLUSIVE PATENT SUBLICENSE AGREEMENTExclusive Patent Sublicense Agreement • May 26th, 2015 • MyDx, Inc. • Plastic material, synth resin/rubber, cellulos (no glass) • California
This EXCLUSIVE PATENT SUBLICENSE AGREEMENT (this “Agreement”) is made as of April 24, 2015 (the “Effective Date”) by and between Next Dimension Technologies, Inc., a corporation organized under the laws of California, having its principal office at 1 West Mountain Street, #11, Pasadena, CA 91102 (“NDT”), and CDx, Inc., a corporation organized under the laws of Delaware, having its principal office at 4225 Executive Square Suite 600, La Jolla, CA 92037 (“CDx”). NDT and CDx are each referred to herein as such or, individually, as a “Party” or, collectively, as “Parties.”
FIRST AMENDMENT TO THE EXCLUSIVE PATENT SUBLICENSE AGREEMENTExclusive Patent Sublicense Agreement • January 13th, 2017 • MyDx, Inc. • Measuring & controlling devices, nec
THIS FIRST AMENDMENT TO THE EXCLUSIVE PATENT SUBLICENSE AGREMENT (this “Sublicense Amendment Agreement”) is made as of November 29, 2016 (the “Effective Date”) by and between CDx, Inc., a Delaware corporation with its principal place of business at 6335 Ferris Square, Suite B, San Diego, CA 92121 (“CDx”), and Next Dimension Technologies, Inc., a California corporation with its principal place of business at 1 West Mountain Street, #11, Pasadena, CA 91103 (“NDT”). CDx and NDT are sometimes referred to herein individually as the “Party” or collectively as the “Parties”.
MWE Execution Copy EXCLUSIVE PATENT SUBLICENSE AGREEMENT (the “Agreement”) BY AND BETWEENExclusive Patent Sublicense Agreement • January 20th, 2021 • Dynacure S.A. • Pharmaceutical preparations
WHEREAS, in the frame of its research activity in the Institut de Génétique et de Biologie Moléculaire et Cellulaire (hereinafter referred to as the “LABORATORY”), the team of Jocelyn LAPORTE has identified and developed a new therapeutic strategy for the treatment of myopathies (“TECHNOLOGY”), and more specifically centronuclear myopathies and Duchenne Muscular Distrophy, objects of patent applications.
